At AACC, Rheonix presented three research studies demonstrating its integrated sample prep and PCR testing platform. In addition, the company reiterated its intent to seek regulatory clearance in the US for a warfarin sensitivity genotyping test by the end of the year; followed by a regulatory submission in China for an HPV test.
Medco Research Institute announced this week that it is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor for the treatment of heartburn. The study will involve genetic testing to establish which patients can respond to Plavix.
CDC's GAPPNet has launched several new online resources for gathering information on available genomic technologies, including a searchable database of genomic applications and a new open-access journal that publishes evidence reviews and summary articles on the validity and utility of genetic tests.
Steven Murphy, founder of the Personalized Medicine Group, last week introduced GeneticHub as an online resource for people around the country seeking doctors with genetic expertise and a high-volume clinical laboratory with appropriate certifications to conduct genetic testing.
The slew of PGx abstracts presented by the drug giant at the annual oncology meeting highlighted its “focused approach to cancer drug development through the identification and validation of molecular targets,” Pfizer said.
NICE's recommendation for NHS to pay for AstraZeneca's non-small cell lung cancer drug Iressa in EGFR mutation-positive patients marks the second personalized medicine product to be funded in the UK after Herceptin was approved in 2002 for HER2-overexpressing breast cancer patients.
The 13 drugs for which CVS Caremark customers will have the option to sign up for genetic testing includes a range of treatments for cancer, HIV, and other indications, but the anticoagulant warfarin is not on the list.
Hal Barron, Genentech's chief medical officer, said that "by using [Dako's] diagnostics to help identify the right patients" who will benefit from treatment, Genentech hopes to make Herceptin "the first targeted option for advanced HER2-positive stomach cancer."
Affomix and the PGx Centre will develop reagents for the quantitative multiplex profiling of candidate biomarkers that may allow clinicians to predict and evaluate how patients respond to novel anti-atherosclerotic agents.